There is a version of mental health care that lives in the break room. It gets passed along between calls, half joke and half warning: get help and you will be pulled off the line, sent somewhere for weeks, and talked about for a year. Some of it has a grain of truth. Most of it is out of date.

This piece takes five of the beliefs we hear most often from police, fire, and EMS about where depression treatment actually happens, and checks them against what is known about the treatments and against a summer poll, funded by our publisher, that reached 443 adults around the Midwest. The survey was a general-population sample, not a responder survey, and every figure below describes all 443 respondents together. The numbers are final, from the validated export; responders and veterans together came to 29 people, not enough for a separate read.

Myth 1: Getting treated means going away somewhere

For most people with depression, treatment is outpatient. You go to an appointment, you go home, you go to work. Inpatient programs exist for people who need more, but they are not the default.

Even the newer options that require supervision are day-visit care. Esketamine nasal spray, marketed as Spravato, is taken at a certified clinic, and you stay for observation afterward. Then you leave with a ride. No overnight stay is involved. Brain Recovery Centers walks through what a Spravato day looks like.

When we asked people how they would want to receive a treatment like this, 44 percent chose an in-person clinic close to home. That is a local building with a parking lot, not a facility three states away.

Myth 2: Everyone wants telehealth now, so that is where care is going

Video visits are genuinely useful for shift workers. But the survey did not show a stampede toward the couch. At-home telehealth was the choice of 22 percent. A slightly larger share, 23 percent, liked a mixed model: begin in the clinic, finish from the living room. Eleven percent said they did not care either way.

Count the clinic-only and hybrid groups together and 67 percent wanted in-person care as at least part of the plan. Telehealth is a tool. For most people it is not a replacement for walking into an office.

For responders, a hybrid setup can be the practical sweet spot: in person for the evaluation and anything that needs monitoring, video for check-ins and therapy that can move when your schedule does.

Myth 3: At-home ketamine is basically the same thing as the clinic version

This is the one that can actually hurt someone.

Spravato is the only drug in this family that is FDA-approved for depression, specifically depression that has not improved on standard antidepressants. Its approval carries conditions: a certified setting administers every dose, staff observe you for a while afterward, and you stay off the road until the following day.

At-home ketamine, typically a lozenge or pill mailed by a telehealth outfit, is not that product and does not come with those safeguards. It is ketamine used off-label, and the quality of screening and follow-up varies enormously between providers. IV ketamine at a clinic is also off-label for depression, though at least it happens under direct observation.

The two are not interchangeable, whatever the marketing says.

Myth 4: If I walk into a clinic, the department will know

Your medical records are protected by federal privacy law, and a clinic generally cannot share them with your employer without your written authorization. The places where information does travel are worth knowing about ahead of time: workers' comp claims, fitness-for-duty exams ordered by your agency, and some department-run programs.

Privacy is a common concern, not a responder quirk. As a top-two provider priority, private or discreet care was chosen by 11 percent of respondents, while 10 percent wanted someone who specializes in veterans and first responders.

Practical steps:

Ask the clinic in writing who can see your chart and under what circumstances.
Use your personal insurance rather than a department program if confidentiality is your priority, and ask your plan how explanation-of-benefits statements are mailed.
If you need a scheduling note, ask the clinician to limit it to dates and times.
Talk to your union representative before filing anything that involves the employer.

Myth 5: The only way in is through the department psychologist

The department clinician or EAP counselor is one door, and sometimes a good one. It is not the only one. The survey's most popular starting point, picked by 56 percent, was simply the family doctor people already see. A psychiatrist or other specialist in mental health would get the first call from 23 percent. And 5 percent confessed to being stumped about where to start.

Your primary doctor can screen you, review what you have already tried, and refer you to a psychiatrist who can evaluate you for newer options.

Trust also runs through that doctor. Of all respondents, 74 percent said a thumbs-up from their own physician would be enough to put them on a new treatment. Family and friends swayed 18 percent. Online voices who are veterans or first responders swayed just 4 percent, which is worth remembering the next time a social media post makes a treatment sound like a sure thing.

What is actually true

Here is the short version, stripped of break-room lore:

The ketamine-family option with FDA approval means clinic visits, observation, and a ride home.
At-home ketamine exists, is off-label, and deserves hard questions.
Your own doctor is a legitimate starting point, and the one most people trust.

Whether any of it suits you turns on your history, and a clinician who has evaluated you should make that call. Read this as background, not medical advice, since no treatment carries any certainty of working.

If you have been carrying calls home and it has started to feel like there is no way out, do not sit on it until the shift ends. A counselor at the Suicide and Crisis Lifeline is a call or text to 988 away, at any hour. They will not judge the job or what it has cost you.

Methodology

Research costs were covered by the publisher, which commissioned the study. Pollfish handled the fieldwork on its consumer panel, and the last day was June 23, 2026. The final sample: n=443 adults between 18 and 64 in ten Midwest states, namely Kansas, Minnesota, Ohio, Iowa, Oklahoma, Wisconsin, Missouri, Indiana, Nebraska, and Illinois. Figures describe the full sample and are final, taken from the validated data.

Break room myths first responders hear about depression care